Breast cancer results in approximately 670,000 deaths each year. In 2022, data from the World Health Organisation (WHO) revealed that breast cancer was the most prevalent cancer among women in 157 out of 185 countries. Every year, over 2 million women receive a breast cancer diagnosis. Given these statistics, early detection of this fatal disease is crucial, along with the development of targeted drugs to combat cancerous cells. The US Food and Drug Administration (FDA) has authorized Kisqali, also known as ribociclib, for early-stage breast cancer treatment. This medication has been approved for use in combination with hormone therapy for patients with early-stage breast cancer, providing an option for individuals concerned about cancer recurrence. The FDA's approval encompasses the use of ribociclib with an aromatase inhibitor as adjuvant therapy for adults with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. Additionally, the FDA has approved a co-pack containing ribociclib and letrozole for the same indication. Kisqali, a selective cyclin-dependent kinase inhibitor manufactured by Novartis, works by targeting and inhibiting two proteins, CDK4 and CDK6, which, when over-activated, can promote rapid growth and division of cancer cells. By blocking these proteins with precision, the drug aims to prevent cancer cells from replicating uncontrollably. Kisqali is administered orally in the form of a pill. The recommended dosage is a daily oral intake of 400 mg for three weeks followed by a one-week break, with this cycle continuing for three years. It can be taken with or without food.Kisqali Ed.: Adverse Effects

Common side effects linked to Kisqali medication include a decrease in white blood cell count, known as neutropenia. Neutropenia involves lower levels of neutrophils in the blood, which are crucial for fighting off infections in the body. Additionally, Kisqali may cause liver-related problems and interstitial lung disease or pneumonitis. Recognizing Early Symptoms of Breast Cancer is Vital.